[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 458
Citations 0
Observation
October 2016

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis

Author Affiliations
  • 1Department of Neurology, St Josef Hospital, Ruhr University of Bochum, Bochum, Germany
  • 2Section of Hematology and Oncology, Medical Department, St Josef Hospital, Ruhr University of Bochum, Bochum, Germany
JAMA Neurol. 2016;73(10):1251-1253. doi:10.1001/jamaneurol.2016.2588

Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis, an autoimmune disease associated with ovarian teratoma, predominantly affects young females.1 Because antibodies against subunits of the NMDAR contribute to the pathogenesis, methods targeting humoral immunity are therapeutically efficacious.2 However, some patients have an unsatisfactory outcome after high-dose corticosteroids, apheresis therapies, or CD20-targeted B-cell depletion with rituximab.2 We describe 2 patients with severe anti-NMDAR encephalitis who received the proteasome inhibitor bortezomib (Velcade), which was well tolerated and followed by marked remission.

First Page Preview View Large
First page PDF preview
First page PDF preview
×